Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:AGIO's Cash-to-Debt is ranked higher than
77% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:AGIO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AGIO' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.82
NAS:AGIO's Equity-to-Asset is ranked higher than
72% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NAS:AGIO: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AGIO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26  Med: 0.67 Max: 0.9
Current: 0.82
0.26
0.9
Interest Coverage No Debt
NAS:AGIO's Interest Coverage is ranked higher than
72% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AGIO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:AGIO' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 12.41
Beneish M-Score: -1.81
WACC vs ROIC
18.66%
-1028.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -480.30
NAS:AGIO's Operating Margin % is ranked lower than
68% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NAS:AGIO: -480.30 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AGIO' s Operating Margin % Range Over the Past 10 Years
Min: -745.84  Med: -152.2 Max: -76.16
Current: -480.3
-745.84
-76.16
Net Margin % -461.78
NAS:AGIO's Net Margin % is ranked lower than
68% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NAS:AGIO: -461.78 )
Ranked among companies with meaningful Net Margin % only.
NAS:AGIO' s Net Margin % Range Over the Past 10 Years
Min: -731.6  Med: -154.25 Max: -80.07
Current: -461.78
-731.6
-80.07
ROE % -52.30
NAS:AGIO's ROE % is ranked lower than
56% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:AGIO: -52.30 )
Ranked among companies with meaningful ROE % only.
NAS:AGIO' s ROE % Range Over the Past 10 Years
Min: -85.73  Med: -49.69 Max: -19.25
Current: -52.3
-85.73
-19.25
ROA % -40.12
NAS:AGIO's ROA % is ranked lower than
54% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:AGIO: -40.12 )
Ranked among companies with meaningful ROA % only.
NAS:AGIO' s ROA % Range Over the Past 10 Years
Min: -51.02  Med: -23.3 Max: -12.13
Current: -40.12
-51.02
-12.13
ROC (Joel Greenblatt) % -1472.98
NAS:AGIO's ROC (Joel Greenblatt) % is ranked lower than
63% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:AGIO: -1472.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AGIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1472.98  Med: -827.83 Max: -516.17
Current: -1472.98
-1472.98
-516.17
3-Year Revenue Growth Rate -21.90
NAS:AGIO's 3-Year Revenue Growth Rate is ranked lower than
70% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:AGIO: -21.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AGIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.9  Med: 8.1 Max: 27.6
Current: -21.9
-21.9
27.6
3-Year EBITDA Growth Rate -62.70
NAS:AGIO's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:AGIO: -62.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AGIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.7  Med: -40.6 Max: -27.1
Current: -62.7
-62.7
-27.1
3-Year EPS without NRI Growth Rate -61.90
NAS:AGIO's 3-Year EPS without NRI Growth Rate is ranked lower than
92% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. NAS:AGIO: -61.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AGIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.3 Max: -21.5
Current: -61.9
GuruFocus has detected 2 Warning Signs with Agios Pharmaceuticals Inc NAS:AGIO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AGIO's 30-Y Financials

Financials (Next Earnings Date: 2019-02-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

AGIO Guru Trades in Q3 2017

George Soros 3,500 sh (New)
Columbia Wanger 889,142 sh (+15.63%)
Vanguard Health Care Fund 3,874,924 sh (unchged)
Steven Cohen 129,640 sh (-36.14%)
» More
Q4 2017

AGIO Guru Trades in Q4 2017

Vanguard Health Care Fund 3,874,924 sh (unchged)
George Soros Sold Out
Columbia Wanger 760,116 sh (-14.51%)
Steven Cohen 91,500 sh (-29.42%)
» More
Q1 2018

AGIO Guru Trades in Q1 2018

Leon Cooperman 45,000 sh (New)
Jim Simons 69,100 sh (New)
Eaton Vance Worldwide Health Sciences Fund 43,741 sh (New)
Steven Cohen 406,090 sh (+343.81%)
Vanguard Health Care Fund 4,353,124 sh (+12.34%)
» More
Q2 2018

AGIO Guru Trades in Q2 2018

Jim Simons Sold Out
Leon Cooperman Sold Out
Vanguard Health Care Fund 4,233,424 sh (-2.75%)
Steven Cohen 155,200 sh (-61.78%)
Eaton Vance Worldwide Health Sciences Fund 31,276 sh (-28.50%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AGIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Agios Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OSTO:SOBI, NAS:UTHR, SZSE:000661, NAS:AVXS, NAS:SRPT, NAS:BPMC, XKRX:128940, SZSE:002007, BOM:532523, HKSE:01548, XBRU:ABLX, HKSE:01530, SHSE:600201, NAS:TECH, NAS:FGEN, SZSE:300347, NAS:AAAP, LSE:BTG, LSE:ABC, TSE:4587 » details
Traded in other countries:8AP.Germany,
Headquarter Location:USA
Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Ratios

vs
industry
vs
history
PB Ratio 5.32
AGIO's PB Ratio is ranked lower than
59% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AGIO: 5.32 )
Ranked among companies with meaningful PB Ratio only.
AGIO' s PB Ratio Range Over the Past 10 Years
Min: 3.8  Med: 6.65 Max: 16.81
Current: 5.32
3.8
16.81
PS Ratio 52.70
AGIO's PS Ratio is ranked lower than
77% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AGIO: 52.70 )
Ranked among companies with meaningful PS Ratio only.
AGIO' s PS Ratio Range Over the Past 10 Years
Min: 17.19  Med: 41.98 Max: 107.02
Current: 52.7
17.19
107.02
EV-to-EBIT -9.46
AGIO's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. AGIO: -9.46 )
Ranked among companies with meaningful EV-to-EBIT only.
AGIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -89.2  Med: -11.4 Max: -4.5
Current: -9.46
-89.2
-4.5
EV-to-EBITDA -9.64
AGIO's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. AGIO: -9.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -91.9  Med: -11.8 Max: -4.6
Current: -9.64
-91.9
-4.6
EV-to-Revenue 45.60
AGIO's EV-to-Revenue is ranked lower than
72% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. AGIO: 45.60 )
Ranked among companies with meaningful EV-to-Revenue only.
AGIO' s EV-to-Revenue Range Over the Past 10 Years
Min: 8.1  Med: 36.7 Max: 101.6
Current: 45.6
8.1
101.6
Current Ratio 8.21
AGIO's Current Ratio is ranked higher than
73% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. AGIO: 8.21 )
Ranked among companies with meaningful Current Ratio only.
AGIO' s Current Ratio Range Over the Past 10 Years
Min: 2.77  Med: 6.33 Max: 10.75
Current: 8.21
2.77
10.75
Quick Ratio 8.20
AGIO's Quick Ratio is ranked higher than
74% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. AGIO: 8.20 )
Ranked among companies with meaningful Quick Ratio only.
AGIO' s Quick Ratio Range Over the Past 10 Years
Min: 2.77  Med: 6.33 Max: 10.75
Current: 8.2
2.77
10.75
Days Inventory 90.65
AGIO's Days Inventory is ranked lower than
99.99% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. AGIO: 90.65 )
Ranked among companies with meaningful Days Inventory only.
AGIO' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 90.65
Current: 90.65
0
90.65
Days Sales Outstanding 40.99
AGIO's Days Sales Outstanding is ranked lower than
80% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. AGIO: 40.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.8  Med: 31.14 Max: 50.78
Current: 40.99
6.8
50.78
Days Payable 8.00
AGIO's Days Payable is ranked lower than
99.99% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. AGIO: 8.00 )
Ranked among companies with meaningful Days Payable only.
AGIO' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8
Current: 8
0
8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.60
AGIO's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. AGIO: -9.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.2  Med: -13.6 Max: -9.6
Current: -9.6
-17.2
-9.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.09
AGIO's Price-to-Net-Cash is ranked lower than
55% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. AGIO: 8.09 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AGIO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.18  Med: 9.45 Max: 15.14
Current: 8.09
6.18
15.14
Price-to-Net-Current-Asset-Value 7.70
AGIO's Price-to-Net-Current-Asset-Value is ranked lower than
57% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. AGIO: 7.70 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AGIO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.79  Med: 8.9 Max: 14.24
Current: 7.7
5.79
14.24
Price-to-Tangible-Book 5.33
AGIO's Price-to-Tangible-Book is ranked higher than
50% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. AGIO: 5.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AGIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.63  Med: 7.02 Max: 10.28
Current: 5.33
4.63
10.28
Price-to-Median-PS-Value 1.26
AGIO's Price-to-Median-PS-Value is ranked lower than
71% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. AGIO: 1.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AGIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 0.97 Max: 2.33
Current: 1.26
0.56
2.33
Earnings Yield (Greenblatt) % -10.55
AGIO's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. AGIO: -10.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AGIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -22.4  Med: -8.8 Max: -1.1
Current: -10.55
-22.4
-1.1

More Statistics

Revenue (TTM) (Mil) $74.17
EPS (TTM) $ -6.26
Beta2.57
Volatility48.26%
52-Week Range $51.62 - 99.82
Shares Outstanding (Mil)58.18

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 87 208 390 583
EBIT (Mil $) -365 -18 45 99
EBITDA (Mil $)
EPS ($) -6.02 -2.80 -1.55 0.37
EPS without NRI ($) -6.02 -2.80 -1.55 0.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}